drugset / Trial / NCT00664222

Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)

NCT00664222

Phase 4 Completed 16 enrolled Tottori University Hospital
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

Timeline

Start
2004-01
Primary completion
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 20 mg
Subject Spironolactone Small molecule 25 mg

Indications